Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

2.840 -0.030 (-1.05%)
Streaming Delayed Price Updated: 2:45 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,227
Open 2.850
Bid (Size) 2.840 (1)
Ask (Size) 2.850 (1)
Prev. Close 2.870
Today's Range 2.820 - 2.893
52wk Range 0.4000 - 5.480
Shares Outstanding 23,541,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
Via TheNewswire.com

Performance

YTD
+342.9%
+342.9%
1 Month
-9.3%
-9.3%
3 Month
+45.6%
+45.6%
6 Month
+336.5%
+336.5%
1 Year
+320.1%
+320.1%

More News

Read More
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
Via NewMediaWire
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
Via TheNewswire.com
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts
Via TheNewswire.com
Topics World Trade
ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma
Via TheNewswire.com
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
Via TheNewswire.com
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
Via NewMediaWire
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025
Via NewMediaWire
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025
Via TheNewswire.com
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program
Via TheNewswire.com
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships
Via TheNewswire.com
Abvc BioPharma Doubles Assets in Q2
Via The Motley Fool
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts
Via NewMediaWire
Topics World Trade
ABVC BioPharma Gains Confidence From International Investors to Support Growth Path
Via NewMediaWire
ABVC BioPharma Gains Confidence From International Investors to Support Growth Path
Via TheNewswire.com
OncoX Deepens ABVC Alliance
Via NewMediaWire
Topics Initial Public Offering
OncoX Deepens ABVC Alliance
Via TheNewswire.com
Topics Initial Public Offering
ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma
Via NewMediaWire
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program
Via NewMediaWire
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships
Via NewMediaWire
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology
Via NewMediaWire
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology
Via TheNewswire.com
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment
Via NewMediaWire

Frequently Asked Questions

Is ABVC BioPharma, Inc. - Common Stock publicly traded?
Yes, ABVC BioPharma, Inc. - Common Stock is publicly traded.
What exchange does ABVC BioPharma, Inc. - Common Stock trade on?
ABVC BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ABVC BioPharma, Inc. - Common Stock?
The ticker symbol for ABVC BioPharma, Inc. - Common Stock is ABVC on the Nasdaq Stock Market
What is the current price of ABVC BioPharma, Inc. - Common Stock?
The current price of ABVC BioPharma, Inc. - Common Stock is 2.840
When was ABVC BioPharma, Inc. - Common Stock last traded?
The last trade of ABVC BioPharma, Inc. - Common Stock was at 09/16/25 02:45 PM ET
What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?
The market capitalization of ABVC BioPharma, Inc. - Common Stock is 66.86M
How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?
ABVC BioPharma, Inc. - Common Stock has 67M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.